Prognostic and predictive factors of invasive ductal breast carcinomas

Journal of B.U.ON.

Volumn 15, Issue 1, 2010, Pages 79-88

  Lialiaris, Theodore S ^a   Georgiou, G ^a   Sivridis, E ^a   Kareli, D ^a   Tripsiannis, G ^a   Papageorgiou, A ^b   Chrisafi, S ^b   Kritsi, Z ^b   Giatromanolaki, A ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

c erbB 2; E cadherin; Estrogen and progesterone receptors; p53; Primary ductal breast carcinoma

Indexed keywords

BIOCHEMICAL MARKER; CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; UVOMORULIN;

ADULT; ARTICLE; C ERBB 2 ONCOGENE; CANCER GRADING; CANCER PATIENT; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENARCHE; ONCOGENE; P53 GENE; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BODY WEIGHT; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CHI-SQUARE DISTRIBUTION; FEMALE; GREECE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950976613     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Cufer T. Reducing the risk of late recurrence in hormone-responsive breast cancer. Ann Oncol 2007; 18 (Suppl): viii 18-25.
2. Harbeck N. Never too late reducing late breast cancer relapse risk. Curr Med Res Opin 2008; 24: 3295-3305.
3. Ernster VL, Ballard-Barbash R, Barlow WE et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002; 94: 1546-1554. (Pubitemid 35277278)
4. Giancotti V. Breast cancer markers. Cancer Lett 2006; 243: 145-159.
5. Tamini RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007; 99: 1178-1187. (Pubitemid 47233068)
6. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168. (Pubitemid 28144151)
7. Reiner A, Reiner G, Spona J, Schemper M, Holzner JH. Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. A comparison of immunocytochemical and biochemical analysis. Cancer 1988; 61: 1149-1154.
8. Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 2005; 93: 221-236.
9. Elliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 2008; 630: 148-165.
10. Stockwell S. Classics in Oncology. George Thomas Beatson, MD (1848-1933). CA Cancer J Clin 1983; 33: 105-121.
11. Korenman SG. The endocrinology of breast cancer. Cancer 1980; 46: 874-878.
12. Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori 2008; 94: 370-383.
13. Leake R, Filipovic S. Current value and future potential of biological markers in breast cancer. J BUON 2002; 7: 319-323. (Pubitemid 36582128)
14. Giatromanolaki A, Koukourakis MI, Simopoulos C et al. C-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res 2004; 10: 7972-7977. (Pubitemid 39587538)
15. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell 2007; 11: 103-105. (Pubitemid 46209856)
16. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A. The association of p53 mutations and p53 codon 72, Her2 codon 655 and MTHFR C677T polymorphisms with breast cancer in northern Greece. Cancer Lett 2005; 222: 57-65.
17. Lukas J, Niu N, Press MF. p53 mutations and expression in breast carcinoma in situ. Am J Pathol 2000; 156: 183-191. (Pubitemid 30644451)
18. Davidoff AM, Kerns BM, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991; 51: 2605-2610.
19. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
20. Cuadros M, Villegas R. Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol 2009; 17: 1-7.
21. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas. Appl Immunohistochem Mol Morphol 2006; 14: 78-82.
22. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005; 17: 499-508.
23. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
24. Histopathology 2002; 41: 151-152, discussion 152-153.
25. Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and BCL-2 expression. Virchows Arch 2001; 438: 470-477. (Pubitemid 32449055)
26. Giatromanolaki A, Sivridis E, Koukourakis MI, Harris AL, Gatter KC. BCL-2 and p53 expression in stage I endometrial carcinoma. Anticancer Res 1998; 18(5B): 3689-3693. (Pubitemid 28564248)
27. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004; 96: 1856-1865.
28. Key T, Appleby P, Barnes I, Reeves G, and the Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-616.
29. Baserga R. The insulin-like growth factor 1 receptor: a key to tumor growth. Cancer Res 1995; 55: 249-252
30. Henderson EB, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427-433
31. Tavani A Gallus S, La Vecchia C et al. Risk factors for breast cancer in women under 40 years. Eur J Cancer 1999; 35: 1361-1367. (Pubitemid 29397437)
32. Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer 2007; 121: 1079-1085. (Pubitemid 47101646)
33. Yumuk PF, Dane F, Yumuk VD et al. Impact of body mass index on cancer development. J BUON 2008; 13: 55-59. (Pubitemid 351460876)
34. Hopton DS, Thorogood J, Clayden AD, Mackinnon D. Histological grading of breast cancer: Significance of grade on recurrence and mortality. Eur J Surg Oncol 1989; 15: 25-31. (Pubitemid 19062350)
35. Tot T. The diffuse type of mvasive carcinoma of the breast: morphology and prognosis. Virchows Arch 2003; 443: 718-724. (Pubitemid 38030624)
36. Muller D, Kohler G, Ohlinger R. Staging procedure in primary breast cancer. Anticancer Res 2008; (4c): 2397-2400.
37. Bremer TM, Jacquemier J, Charafe-Jauffret E, Viens P, Birnbaum D, Linke SP. Prognostic marker profile to assess risk in stage I-III hormone receptor positive breast cancer patients. Int J Cancer 2009; 124: 826-904.
38. Carter LC, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-187. (Pubitemid 19032001)
39. Iiyas M. Adhesion molecule expression in breast cancer: the phoenix in tumour metastasis? J Pathol 2000; 190: 3-5.
40. Fitzgibbons PL, Page DL, Weaver D et al. Prognostic factors in breast cancer. Arch Pathol Lab Med 2000; 124: 966-978.
41. Thor AD, Liu S, Edgerton S et al. Activation (tyrosine phosphorylation) of erbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer; J Clin Oncol 2000; 18: 3230-3239.
42. Reed W, Hannisdal E, Boehler PJ et al. The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma. Cancer 2000; 88: 804-813.
43. Yang XR, Pfeiffetr RM, Garcia-Closas M et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res 2007; 67: 10608-10617. (Pubitemid 350070838)
44. Tayi J, Kaiman T, Bankfalvi A, Willibald S, Werner R, Laszlo F. Analysis of p53 mutation and cyclin D1 expression in breast cancer. Pathol Oncol Res 1999; 5: 90-94. (Pubitemid 29352596)
45. Ioakim-Liossi A, Karakitsos P, Markopoulos C et al. p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas. Cytopathology 2001; 12: 197-202. (Pubitemid 32574972)
46. Gohring UJ, Scharl A, Heckel C, Achr A, Crombach G. P53 protein in 204 patients with primary breast carcinoma: immunohistochemical detection and clinical values as a prognostic factor. Arch Gynecol Obstet 2001; 256: 139-146.
47. Mazars R, Spinardi L, BenCheikh M, Simony-Lafontaine J, Jeanteur P, Theillet S. P53 mutations occur in aggressive breast cancer. Cancer Res 1993; 52: 3918-3923.
48. Adzic M, Niciforovic A, Neskovic-Konstantinovic Z, Radojcic MB. Superoxide dismutases and p53 protein levels in blood cells of breast cancer patients. J BUON 2004; 9: 283-287. (Pubitemid 40360804)
49. Madhavan M, Srinivas P, Abraham E et al. Cadherins as predictive markers of nodal metastasis in breast cancer. Mod Pathol 2001; 14: 423-427. (Pubitemid 32448740)
50. Heimann R, Lan F, McBride R, Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res 2000; 60: 298-304. (Pubitemid 30070755)
51. Goyal A, Martin AT, Mansel ER, Jiang GW. Real-time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome. World Surg Oncol 2008; 6: 56-61. (Pubitemid 351891433)
52. Korkolis C, Ardavanis A, Yoyis J, Kyroudi A, Gorgoulis V, Kittas C. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters. p53 oncoprotein and cathepsin-D. Anticancer Res 2001; 21: 2207-2212. (Pubitemid 32728891)
53. Meijnen P, Petersen JL, Antonini N, Rutgers EJT, van de Vijver MJ. Immunohistochemical categorization of ductal carcinoma in situ of the breast. Br J Cancer 2008; 98: 137-142.
54. Bukholm IR, Nesland JM, Bukholm G. Expression of adhesion proteins E-cadherin, alpha-catenin, beta-catenin and gamma-catenin is different in T1 and T2 breast tumours. Pathology 2006; 38: 403-407.